RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027

Peter K. Kaiser, R. C.Andrew Symons, Syed Mahmood Shah, Edward J. Quinlan, Homayoun Tabandeh, Diana V Do, Gail Reisen, Jennifer A. Lockridge, Brian Short, Roberto Guerciolini, Quan Dong Nguyen

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Purpose: To assess the safety, tolerability, pharmacokinetics, and dose-limiting toxicity of single intravitreal injection of Sirna-027, a small interfering RNA targeting vascular endothelial growth factor receptor-1, in patients with choroidal neovascularization (CNV) resulting from neovascular age-related macular degeneration (AMD). Secondary objectives included assessment of anatomic changes in retinal thickness, size of CNV, and changes in visual acuity. Design: Prospective, open-label, single-dose, dose-escalation phase 1 study. Methods: Twenty-six eyes of 26 patients with a median age of 82 years and CNV resulting from AMD who had previous treatments with other therapies were treated at 2 academic retinal practices. Patients received a single dose of Sirna-027 (100, 200, 400, 800, 1200, or 1600 μg/eye). Blood was sampled for pharmacokinetic analysis at 1, 4, and 24 hours after injection and on day 7. Patients underwent ophthalmic examinations including visual acuity, fluorescein angiography, and optical coherence tomography at screening and days 7, 14, 28, and 84. The main outcome measures were adverse reactions and dose-limiting toxicities. Results: Intravitreal injection of a single dose of Sirna-027 from 100 to 1600 μg was well tolerated in patients with AMD, with no dose-limiting toxicity found. Adverse events were mild to moderate in severity. Adjusted mean foveal thickness decreased within 2 weeks after study treatment. The decrease was most pronounced in the 100- and 200-μg doses. Conclusions: A single intravitreal dose of Sirna-027 up to 1600 μg/eye was well tolerated in patients with CNV resulting from neovascular AMD that had been refractory to other therapies. Stabilization or improvement in visual acuity and foveal thickness was observed. No dose-response or dose-limiting effects were noted.

Original languageEnglish (US)
JournalAmerican Journal of Ophthalmology
Volume150
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Macular Degeneration
RNA Interference
Choroidal Neovascularization
Visual Acuity
Intravitreal Injections
Therapeutics
Pharmacokinetics
Vascular Endothelial Growth Factor Receptor-1
Fluorescein Angiography
Optical Coherence Tomography
Small Interfering RNA
Outcome Assessment (Health Care)
Safety
Injections

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Kaiser, P. K., Symons, R. C. A., Shah, S. M., Quinlan, E. J., Tabandeh, H., Do, D. V., ... Nguyen, Q. D. (2010). RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027. American Journal of Ophthalmology, 150(1). https://doi.org/10.1016/j.ajo.2010.02.006

RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027. / Kaiser, Peter K.; Symons, R. C.Andrew; Shah, Syed Mahmood; Quinlan, Edward J.; Tabandeh, Homayoun; Do, Diana V; Reisen, Gail; Lockridge, Jennifer A.; Short, Brian; Guerciolini, Roberto; Nguyen, Quan Dong.

In: American Journal of Ophthalmology, Vol. 150, No. 1, 01.01.2010.

Research output: Contribution to journalArticle

Kaiser, PK, Symons, RCA, Shah, SM, Quinlan, EJ, Tabandeh, H, Do, DV, Reisen, G, Lockridge, JA, Short, B, Guerciolini, R & Nguyen, QD 2010, 'RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027', American Journal of Ophthalmology, vol. 150, no. 1. https://doi.org/10.1016/j.ajo.2010.02.006
Kaiser, Peter K. ; Symons, R. C.Andrew ; Shah, Syed Mahmood ; Quinlan, Edward J. ; Tabandeh, Homayoun ; Do, Diana V ; Reisen, Gail ; Lockridge, Jennifer A. ; Short, Brian ; Guerciolini, Roberto ; Nguyen, Quan Dong. / RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027. In: American Journal of Ophthalmology. 2010 ; Vol. 150, No. 1.
@article{2b9bace1c67640b48d60adee36f6cb89,
title = "RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027",
abstract = "Purpose: To assess the safety, tolerability, pharmacokinetics, and dose-limiting toxicity of single intravitreal injection of Sirna-027, a small interfering RNA targeting vascular endothelial growth factor receptor-1, in patients with choroidal neovascularization (CNV) resulting from neovascular age-related macular degeneration (AMD). Secondary objectives included assessment of anatomic changes in retinal thickness, size of CNV, and changes in visual acuity. Design: Prospective, open-label, single-dose, dose-escalation phase 1 study. Methods: Twenty-six eyes of 26 patients with a median age of 82 years and CNV resulting from AMD who had previous treatments with other therapies were treated at 2 academic retinal practices. Patients received a single dose of Sirna-027 (100, 200, 400, 800, 1200, or 1600 μg/eye). Blood was sampled for pharmacokinetic analysis at 1, 4, and 24 hours after injection and on day 7. Patients underwent ophthalmic examinations including visual acuity, fluorescein angiography, and optical coherence tomography at screening and days 7, 14, 28, and 84. The main outcome measures were adverse reactions and dose-limiting toxicities. Results: Intravitreal injection of a single dose of Sirna-027 from 100 to 1600 μg was well tolerated in patients with AMD, with no dose-limiting toxicity found. Adverse events were mild to moderate in severity. Adjusted mean foveal thickness decreased within 2 weeks after study treatment. The decrease was most pronounced in the 100- and 200-μg doses. Conclusions: A single intravitreal dose of Sirna-027 up to 1600 μg/eye was well tolerated in patients with CNV resulting from neovascular AMD that had been refractory to other therapies. Stabilization or improvement in visual acuity and foveal thickness was observed. No dose-response or dose-limiting effects were noted.",
author = "Kaiser, {Peter K.} and Symons, {R. C.Andrew} and Shah, {Syed Mahmood} and Quinlan, {Edward J.} and Homayoun Tabandeh and Do, {Diana V} and Gail Reisen and Lockridge, {Jennifer A.} and Brian Short and Roberto Guerciolini and Nguyen, {Quan Dong}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.ajo.2010.02.006",
language = "English (US)",
volume = "150",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027

AU - Kaiser, Peter K.

AU - Symons, R. C.Andrew

AU - Shah, Syed Mahmood

AU - Quinlan, Edward J.

AU - Tabandeh, Homayoun

AU - Do, Diana V

AU - Reisen, Gail

AU - Lockridge, Jennifer A.

AU - Short, Brian

AU - Guerciolini, Roberto

AU - Nguyen, Quan Dong

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Purpose: To assess the safety, tolerability, pharmacokinetics, and dose-limiting toxicity of single intravitreal injection of Sirna-027, a small interfering RNA targeting vascular endothelial growth factor receptor-1, in patients with choroidal neovascularization (CNV) resulting from neovascular age-related macular degeneration (AMD). Secondary objectives included assessment of anatomic changes in retinal thickness, size of CNV, and changes in visual acuity. Design: Prospective, open-label, single-dose, dose-escalation phase 1 study. Methods: Twenty-six eyes of 26 patients with a median age of 82 years and CNV resulting from AMD who had previous treatments with other therapies were treated at 2 academic retinal practices. Patients received a single dose of Sirna-027 (100, 200, 400, 800, 1200, or 1600 μg/eye). Blood was sampled for pharmacokinetic analysis at 1, 4, and 24 hours after injection and on day 7. Patients underwent ophthalmic examinations including visual acuity, fluorescein angiography, and optical coherence tomography at screening and days 7, 14, 28, and 84. The main outcome measures were adverse reactions and dose-limiting toxicities. Results: Intravitreal injection of a single dose of Sirna-027 from 100 to 1600 μg was well tolerated in patients with AMD, with no dose-limiting toxicity found. Adverse events were mild to moderate in severity. Adjusted mean foveal thickness decreased within 2 weeks after study treatment. The decrease was most pronounced in the 100- and 200-μg doses. Conclusions: A single intravitreal dose of Sirna-027 up to 1600 μg/eye was well tolerated in patients with CNV resulting from neovascular AMD that had been refractory to other therapies. Stabilization or improvement in visual acuity and foveal thickness was observed. No dose-response or dose-limiting effects were noted.

AB - Purpose: To assess the safety, tolerability, pharmacokinetics, and dose-limiting toxicity of single intravitreal injection of Sirna-027, a small interfering RNA targeting vascular endothelial growth factor receptor-1, in patients with choroidal neovascularization (CNV) resulting from neovascular age-related macular degeneration (AMD). Secondary objectives included assessment of anatomic changes in retinal thickness, size of CNV, and changes in visual acuity. Design: Prospective, open-label, single-dose, dose-escalation phase 1 study. Methods: Twenty-six eyes of 26 patients with a median age of 82 years and CNV resulting from AMD who had previous treatments with other therapies were treated at 2 academic retinal practices. Patients received a single dose of Sirna-027 (100, 200, 400, 800, 1200, or 1600 μg/eye). Blood was sampled for pharmacokinetic analysis at 1, 4, and 24 hours after injection and on day 7. Patients underwent ophthalmic examinations including visual acuity, fluorescein angiography, and optical coherence tomography at screening and days 7, 14, 28, and 84. The main outcome measures were adverse reactions and dose-limiting toxicities. Results: Intravitreal injection of a single dose of Sirna-027 from 100 to 1600 μg was well tolerated in patients with AMD, with no dose-limiting toxicity found. Adverse events were mild to moderate in severity. Adjusted mean foveal thickness decreased within 2 weeks after study treatment. The decrease was most pronounced in the 100- and 200-μg doses. Conclusions: A single intravitreal dose of Sirna-027 up to 1600 μg/eye was well tolerated in patients with CNV resulting from neovascular AMD that had been refractory to other therapies. Stabilization or improvement in visual acuity and foveal thickness was observed. No dose-response or dose-limiting effects were noted.

UR - http://www.scopus.com/inward/record.url?scp=77953909544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953909544&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2010.02.006

DO - 10.1016/j.ajo.2010.02.006

M3 - Article

VL - 150

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -